Heart failure & cardiomyopathiesRandomised controlled trial
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
- Randomised controlled trial
- multicentre
- open-label
Authors' conclusion
Dapagliflozin was not associated with a statistically significant reduction in weight-based diuretic efficiency but was associated with evidence for enhanced diuresis among patients with AHF.
Study context
- Population
- Patients hospitalised for hypervolemic acute HF, randomised within 24 hours of presentation
- Participants
- 240 patients
- Comparison
- Dapagliflozin vs structured usual care
- Primary endpoint
- Diuretic efficiency (cumulative weight change per cumulative loop diuretic dose)
- Follow-up
- Until day 5 or hospital discharge
Primary result
Diuretic efficiency
Odds ratio
0.65
95% CI 0.41–1.02
P = 0.06
Dapagliflozin vs Usual care
OR 0.65 (95% CI 0.41–1.02); P = 0.06
As reported in the abstract
Further findings
Cumulative loop diuretic dose
P = 0.006
Intravenous diuretic up-titrations
- Fewer with dapagliflozin
- P ≤ 0.05
Median 24-hour natriuresis
- Improved with dapagliflozin
- P = 0.03
Urine output
- Improved with dapagliflozin
- P = 0.005
Safety
Diabetic, renal or CV safety events
- Not increased by early dapagliflozin initiation
- adjudicated by a blinded committee
Original publication
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. J Am Coll Cardiol. Published 9 April 2024. doi:10.1016/j.jacc.2024.02.009
Summarised from the published abstract; every number is checked against it